The shares were purchased at an average cost of $1.83 per share, with a total value of $366,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
On Tuesday, October 10th, Wei-Wu He acquired 100,000 shares of CASI Pharmaceuticals stock. Moreover, Wellington Shields Management Limited has 0.12% invested in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 726,069 shares. The shares were bought at an average price of $1.75 per share, for a total transaction of $303,625.00. Blackrock holds 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 294,225 shares. Prnewswire.com's news article titled: "CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global ..." with publication date: September 06, 2017 was also an interesting one.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. (CASI) opened at 3.28 on Thursday. Cinedigm Corp. sank -54.67% from their peak of $3 and now has a $18.66 million market value of equity.
The stock has a 50 day moving average of $1.43 and a 200 day moving average of $1.16. Raymond James Finance Service Inc stated it has 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI).
The company had seen its current volume reaching at 0.5 million shares in the last trade. Shares of CASI Pharmaceuticals, Inc.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally copied and reposted in violation of USA and worldwide copyright and trademark law.
While taking a look at financials, we can look at a number of key indicators about CASI Pharmaceuticals, Inc.
Several equities analysts have weighed in on the company. Finally, HC Wainwright reissued a "buy" rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the company a "buy" rating in a report on Monday, August 14th. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel.
If we look at the Volatility of CASI Pharmaceuticals, Inc. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. The Company operates through the development of targeted therapeutics primarily for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.